Management Team
Hua Chien Chen, Ph.D | Chief Executive Officer
Dr. Hua-Chien Chen received his Ph.D. in Biochemistry from National Yang-Ming University in Taiwan and did his postdoctoral training in Molecular Biology at Case Western Reserve University in US. In 1998, he joined the National Health Research Institute as an Assistant Investigator to discover and develop molecular targets for new drugs. In 2001, Dr. Chen moved to TaiGen Biotechnology as the Biology Director and was in charge of the company’s drug screening program. From 2006 to 2014, Dr. Chen was an Associate Professor at Chang Gung University where he taught Biochemistry and Genomics. He also established a multiplexed micro-RNA quantification platform for Chang Gung Molecular Medicine Research Center to discover and develop non-invasive biomarkers for cancer and other diseases. Dr. Chen specializes in Molecular Biology, Genomics and Cancer Biology. He has many years of experience in biotech industry and is familiar with molecular biology and sequencing-related technology, as well as project evaluation and license negotiation. As the Founder and the Chief Executive Officer, Dr. Chen will oversee the management and operation of ACT Genomics. He will also participate in the R&D program for future application.
Su Jen Chen, Ph.D | Chief Scientific Officer
Dr. Shu-Jen Chen received her Ph.D. in Biochemistry from Virginia Commonwealth University, did her postdoctoral training at Baylor College of Medicine, and then was a Research Assistant Professor at SUNY Buffalo. She joined the National Health Research Institute in 1998 as an Assistant Investigator and established the high throughput screening program for the institute. Dr. Chen moved to TaiGen Biotechnology in 2001 to serve as the Head of In Vitro Pharmacology. In 2006, she joined Chang Gung University. As an Associate Professor at the Department of Biomedical Sciences, she taught Cancer Biology, Drug Discovery and Development, and Biological Database. She also established the Next-Generation Sequencing core facility for Chang Gung Molecular Medicine Research Center. Dr. Chen specializes in automated drug screening system, biological database and data analysis. She has many years of experience in cancer drug discovery and next-generation sequencing operations. She is also familiar with system integration and database design. As the Founder and the Chief Scientific Officer, Dr. Chen will lead the sequencing group, the bioinformatics group, and the R&D group at ACT Genomics to develop and implement cancer genome sequencing for clinical and research application.
Joe Hsueh, MBA | Chief Operating Officer
Joe Hsueh received his MBA from Fairleigh Dickinson University in USA, and B.A. in Microbiology from Soochow University in Taiwan. Combining solid academic discipline and business knowledge, he has 15 years of managerial experience in operations, finance and business development at a reputable biopharmaceutical company, TaiGen Biotechnology in Taiwan. During the period of working for TaiGen, he had completed 2 series, co-conducted 1 series of financing and successfully closed in total of 114 Million US$ within 7 years, inked an out-licensing deal, and involved in various tasks and business networking in Biopharmaceuticals/Pharmaceutical industry. Before joining TaiGen, he had worked for Chengxin VC and led fund-raising for 6 companies in the States and Taiwan. Mr. Hsueh will be in charge of finance operation, sales/ marketing and business development team to foresee business opportunities for future growth.